Abstract:Abstract Introduction High relapse rate has always been the primary element threatening the long-term survival of acute lymphoblastic leukemia (ALL). The risk stratification depending on conventional prognostic factors indeed assists to detect patients with high risk of relapse, but not efficiently. The detection of minimal residual disease (MRD) has been widely used to further identify patients with poor prognosis. Lots of studies focused at pediatric ALL had demonstrated the prognostic effect of MRD levels for predicting relapse risk and survival in children, but the data and evidences seemed not that sufficient in adult ALL. And it was still unknown to what extent of the MRD levels at remission that the allogenic hematopoietic stem cell transplantation (allo-HSCT) should be implemented. This study was designed to evaluate the prognostic effect of MRD levels at time of CR1 and transplant for adult Philadelphia chromosome-negative ALL (Ph-negative ALL), and to discover the subgroup that benefits from HSCT based on the stratification by the MRD levels at CR1. Methods During January 2006 to December 2011, 107 adult Ph-negative ALL patients in our center were admitted in this study, of whom 45 were assigned chemotherapy and 62 allo-HSCT. All the patients received induction mainly composed of vincristine and corticosteroids (VDP, VDCP, VDLP, VDCLP), and consolidation of VDCP, VMCP, hyper-CVAD etc. For patients allocated allo-HSCT, conditioning regimen mainly involved BuCy without total body irradiation, and the grafts were from alternative donors—15 HLA-matched sibling donors (24.2%), 27 unrelated donors (43.5%), 20 haploidentical donors (32.3%). The bone marrow samples were collected for MRD detection by 4 color flow cytometry. The time point for MRD detection in chemotherapy arm was the first morphologic remission, defined as MRD at CR1; and the HSCT arm added MRD at transplant (the MRD levels just before HSCT) in addition. As some samples lost in the final statistical analysis, there were totally 36 MRD at CR1 samples in chemotherapy arm, 47 MRD at CR1 and 61 MRD at transplant samples in HSCT arm. Comparing and analyzing the differences of survival among risk groups stratified by MRD levels with the cut-off of 0.02% and 0.2%. Further, within the same MRD at CR1 levels, the differences of survival between chemotherapy and HSCT arms were examined to discover the subgroups benefited from allo-HSCT. Results The HSCT arm had a 3-year improved OS and DFS than chemotherapy arm (55.7% vs. 27.9%, P=0.002; 54.4% vs. 18.2%, P<0.001). The relapse rate was significantly lower in the HSCT arm (29.9% vs. 76.5%, P<0.001). In the chemotherapy arm, the 3-year OS for MRD at CR1≤0.02%, 0.02%0.2% were 70.0%, 24.8%, 0% (P=0.005, Figure 1a); In the HSCT arm, the 3-year OS for MRD at CR1≤0.02%, 0.02%0.2% were 81.8%, 58.4%, 23.4% (P=0.004, Figure 1b); and the 3-year OS for MRD at transplant≤0.02%, 0.02%0.2% were 84.6%, 59.3%, 30.0% (P=0.020, Figure 1c). Then, the 3-year improved OS with HSCT was observed in the MRD at CR1>0.02% subgroup (0.02%0.2%, HSCT 23.4% vs. chemotherapy 0%, P=0.016, Figure 1f), but not in the MRD at CR1≤0.02% subgroup (HSCT 81.8% vs. chemotherapy 70.0%, P=0.666, Figure 1d). Multivariate Cox analysis confirmed that higher levels of MRD at CR1 and MRD at transplant were the most statistically significant adverse factors for OS. Conclusions MRD levels at time of CR1 and transplant can strongly predict the outcome of adult Ph-negative ALL; the subgroup whose MRD at CR1>0.02% benefits from allo-HSCT. Disclosures: No relevant conflicts of interest to declare.

A Simple and Predictive Index for the Evaluation of Risk Stratification Following Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Remission.

Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation.

Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies.

Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia

High Risk Factors of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-Hsct) for Leukemia.

A Multifactorial Risk Scoring System for the Prediction of Early Relapse in CMML Patients with Allo-Hsct: a Nationwide Representative Multicenter Study

A novel prognostic scoring system for AML patients undergoing allogeneic hematopoietic stem cell transplantation with real world validation

Outcome and Prognostic Factors of High-Risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

A new multi-factor risk score system for predicting the outcome after allogenic hematopoietic stem cell transplantation]

Risk Stratification-Directed Donor Lymphocyte Infusion Could Reduce Relapse Of Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation

Minimal Residual Disease Levels at Time of CR1 and Transplant Predict Outcome in Philadelphia Chromosome-Negative Adult ALL

Evaluation of the Impact of the Disease Risk Index and Pre-Transplant Measurable Residual Disease By Flow Cytometry As Prognostic Factors in Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study

The Clinical Analysis of Haploidentical Stem Cell Transplantation in Myelodysplastic Syndrome-Associated Acute Myeloid Leukemia

A Novel Risk Model for Predicting Early Relapse in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

Risk-Stratification Treatment Directed By Minimal Residual Disease Improves The Outcome Of Acute Myeloid Leukemia With T(8;21) In First Complete Remission: Results Of The Aml05 Multicentre Trial

Prognostic Factors and Clinical Outcomes in Patients with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation

A Risk Score for Mortality after Allogeneic Hematopoietic Cell Transplantation

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation